VYNDAMAX for ATTR-CM—a convenient single-capsule, once-daily dose
A single VYNDAMAX 61-mg capsule is bioequivalent to VYNDAQEL® (tafamidis meglumine) 80 mg (four 20-mg capsules) and is not interchangeable on a per-mg basis.
As determined by the predefined 90% confidence interval criteria of 80%-125% bioequivalence limits for tafamidis area under curve (AUC) and peak plasma concentration (Cmax) after repeated oral daily dosing for 7 days.1
  • Can be taken with or without food
  • The capsule should be swallowed whole and not crushed or cut
*Capsule shown is not actual size.

1. Tankisheva E. A phase 1, open-label, randomized, crossover, multiple dose, pivotal bioequivalence study to compare PF-06291826 4 × 20 mg tafamidis meglumine and 61 mg: tafamidis free acid soft gelatin capsules administered under fasted conditions to healthy volunteers. Full Clinical Study Report [protocol B3461056]. July 23, 2018.